Known for its creative partnering savvy, Celgene Corp. has transformed itself into a serious contender in immuno-oncology through two key partnerships, spending nearly $1.5 billion upfront across the two deals – a staggering amount of money that reflects the high value of cancer immunotherapy today.
The first deal was with AstraZeneca PLC’s Medimmune unit on a mid-stage immune checkpoint inhibitor [See Deal] and the most recent with Juno Therapeutics Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?